Medical technology company Abanza has received FDA 510(k) clearance for QuadLock, a fixation system for ACL reconstruction.
The system can be used across several graft configurations that are commonly used in ACL procedures, such as quadriceps tendon, quadrupled semitendinosus/gracilis, and bone–patellar tendon–bone, according to a Jan. 27 news release from Abanza.
The knotless, bidirectional tension-adjustable fixation system displayed a 500% reduction in cyclic displacement compared to conventional fixation methods during biomechanical testing.
There are about 300,000 ACL reconstruction surgeries performed in the U.S. each year, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.